一种人工智能设计的癌症疫苗在晚期黑色素瘤患者中显示出75%的反应率,免疫力强,两年后92%的患者没有复发. An AI-designed cancer vaccine showed 75% response rate in advanced melanoma patients, with strong immunity and no relapse in 92% at two years.

Evaxion A/S报告说,其AI设计的癌症疫苗EVX-01在高级黑素瘤患者中进行了第二阶段试验,试验显示75%的客观反应率,16个患者中有12个作了答复,包括4个完整的答复,结果有望在两年内取得成效。 Evaxion A/S reported promising two-year results from a phase 2 trial of its AI-designed cancer vaccine EVX-01 in advanced melanoma patients, showing a 75% objective response rate, with 12 of 16 patients responding, including four complete responses. 所有患者的免疫反应都很强,92%的患者在24个月时没有复发。 All patients mounted strong immune responses, and 92% remained free of relapse at 24 months. 这些疫苗,加上Pembromizumab, 被很好地接种。 The vaccine, combined with pembrolizumab, was well-tolerated. 数据在ESMO大会2025上发表,并计划进行进一步分析. Data were presented at ESMO Congress 2025, with further analysis planned.